Analysis Tools
mortality/aging
|
• median survival time is 6 weeks from the start of tamoxifen administration, with 100% mortality observed at 10 weeks after tamoxifen treatment
|
cardiovascular system
|
• at 4 weeks after tamoxifen treatment, volume-to-mass ratio is increased by ~0.68 uL/mg
|
|
• at 4 weeks after tamoxifen treatment, heart weight-to-body weight ratio is increased by ~2.9 mg/g
|
|
• at 4 weeks after tamoxifen treatment, mice develop cardiac fibrosis as revealed by Massons trichrome staining; qRT-PCR analysis indicates significant upregulation of the pro-fibrotic markers Col1a1, Col3a1, Tgfb1
|
|
• at 4 weeks after tamoxifen treatment, mice exhibit basal cardiac dysfunction consistent with heart failure
• however, H&E staining shows no major cardiac structural abnormalities
|
|
• at 4 weeks after tamoxifen treatment, echocardiography shows a ~50% reduction in ejection fraction in both sexes, along with an ~69 uL increase in end diastolic volume and an ~66 uL increase in end systolic volume
• however, no difference is observed in the heart rate relative to controls
|
|
• at 4 weeks after tamoxifen treatment, mice exhibit lethal heart failure
|
muscle
|
• at 4 weeks after tamoxifen treatment, mice exhibit basal cardiac dysfunction consistent with heart failure
• however, H&E staining shows no major cardiac structural abnormalities
|
|
• at 4 weeks after tamoxifen treatment, echocardiography shows a ~50% reduction in ejection fraction in both sexes, along with an ~69 uL increase in end diastolic volume and an ~66 uL increase in end systolic volume
• however, no difference is observed in the heart rate relative to controls
|
growth/size/body
|
• at 4 weeks after tamoxifen treatment, volume-to-mass ratio is increased by ~0.68 uL/mg
|
|
• at 4 weeks after tamoxifen treatment, heart weight-to-body weight ratio is increased by ~2.9 mg/g
|
